CASTAGNA, ANTONELLA
 Distribuzione geografica
Continente #
NA - Nord America 16.973
EU - Europa 16.766
AS - Asia 15.347
SA - Sud America 3.736
Continente sconosciuto - Info sul continente non disponibili 1.223
AF - Africa 343
OC - Oceania 26
Totale 54.414
Nazione #
US - Stati Uniti d'America 15.895
RU - Federazione Russa 8.878
SG - Singapore 5.326
CN - Cina 5.071
BR - Brasile 3.057
IT - Italia 2.576
HK - Hong Kong 1.740
VN - Vietnam 1.509
SE - Svezia 1.451
RO - Romania 793
FR - Francia 744
DE - Germania 732
CA - Canada 523
GB - Regno Unito 471
BD - Bangladesh 420
IN - India 296
AR - Argentina 269
FI - Finlandia 255
MX - Messico 182
AT - Austria 172
ID - Indonesia 152
PL - Polonia 141
ZA - Sudafrica 124
IQ - Iraq 122
NL - Olanda 117
EC - Ecuador 111
ES - Italia 104
JP - Giappone 101
TR - Turchia 97
CO - Colombia 86
IE - Irlanda 65
PK - Pakistan 62
JM - Giamaica 60
VE - Venezuela 58
LT - Lituania 56
CR - Costa Rica 55
UA - Ucraina 55
PY - Paraguay 50
MA - Marocco 48
MY - Malesia 48
CL - Cile 47
SA - Arabia Saudita 47
HN - Honduras 43
PH - Filippine 40
GT - Guatemala 39
UZ - Uzbekistan 39
EG - Egitto 37
NI - Nicaragua 37
AE - Emirati Arabi Uniti 31
TT - Trinidad e Tobago 30
TN - Tunisia 29
NP - Nepal 28
IR - Iran 26
IL - Israele 23
KE - Kenya 23
BE - Belgio 22
AU - Australia 21
PE - Perù 21
UY - Uruguay 21
DZ - Algeria 20
DO - Repubblica Dominicana 19
TH - Thailandia 19
KR - Corea 17
PR - Porto Rico 17
AZ - Azerbaigian 16
KZ - Kazakistan 16
MD - Moldavia 15
CH - Svizzera 14
OM - Oman 14
SV - El Salvador 14
AL - Albania 13
LB - Libano 13
CW - ???statistics.table.value.countryCode.CW??? 12
JO - Giordania 12
SY - Repubblica araba siriana 12
EU - Europa 11
PT - Portogallo 11
BB - Barbados 10
BO - Bolivia 10
CI - Costa d'Avorio 10
GP - Guadalupe 10
PA - Panama 10
CZ - Repubblica Ceca 9
EE - Estonia 9
NG - Nigeria 9
ET - Etiopia 8
RS - Serbia 8
BZ - Belize 7
HR - Croazia 7
KW - Kuwait 7
LU - Lussemburgo 7
NO - Norvegia 7
BS - Bahamas 6
AM - Armenia 5
BH - Bahrain 5
DK - Danimarca 5
GA - Gabon 5
GE - Georgia 5
GR - Grecia 5
QA - Qatar 5
Totale 53.110
Città #
Singapore 2.473
Dallas 2.300
Ashburn 2.275
Moscow 1.931
San Jose 1.884
Hong Kong 1.717
Council Bluffs 869
Shanghai 824
Milan 797
Hefei 685
Lauterbourg 590
New York 577
Princeton 552
Beijing 551
Lawrence 543
Ho Chi Minh City 526
Shenzhen 447
Santa Clara 346
Los Angeles 337
Hanoi 335
São Paulo 282
Phoenix 260
Nuremberg 203
Munich 201
Rome 167
Orem 162
Helsinki 156
Miano 138
Montreal 134
Boardman 128
Denver 125
Atlanta 119
Warsaw 116
Chicago 101
Brooklyn 99
Rio de Janeiro 94
London 89
Tokyo 88
Toronto 88
Houston 87
Chennai 84
Guangzhou 84
Da Nang 83
Washington 76
Johannesburg 73
Poplar 70
Haiphong 69
Naples 67
Vienna 67
Frankfurt am Main 66
Mexico City 66
Seattle 64
Stockholm 64
Curitiba 61
North Bergen 61
Belo Horizonte 60
Manchester 60
Amsterdam 59
Dublin 59
Turku 58
Brasília 57
Baghdad 52
Buffalo 49
Campinas 47
Philadelphia 47
Boston 45
Miami 45
Porto Alegre 44
Quito 43
San José 43
Biên Hòa 42
Bologna 42
Florence 41
San Francisco 40
Turin 40
Cesano Boscone 39
Falkenstein 39
Lappeenranta 38
Las Vegas 38
Tashkent 38
Pune 37
Managua 36
Ankara 35
Columbus 34
Guayaquil 34
Kingston 34
Hangzhou 33
Mumbai 33
Hải Dương 32
The Dalles 32
Brescia 29
Tianjin 29
Charlotte 28
Salvador 28
St Petersburg 28
Genoa 26
Jakarta 26
Querétaro 26
Barnet 25
Dhaka 25
Totale 26.226
Nome #
The 118I reverse transcriptase mutation is the only independent genotypic predictor of virologic failure to a stavudine-containing salvage therapy in HIV-1-infected patients 1.375
Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population 476
What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres 279
Monkeypox in a patient with undifferentiated connective tissue disease 260
The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment 259
Viral bloodstream detection in mpox patients: An observational multicentric study 242
Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors 222
Meningococcus B Vaccination Effectiveness Against Neisseria gonorrhoeae Infection in People Living With HIV: A Case-Control Study 211
High Risk of Secondary Infections Following Thrombotic Complications in Patients With COVID-19 195
Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency 195
Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 192
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Focus on the Pathophysiological and Diagnostic Role of Viruses 169
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study 165
The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia 164
Gas-exchange deficit and systemic hypoperfusion in COVID-19 and non-COVID-19 young adult patients with pneumonia 164
Case Report: Favorable outcome of allogeneic hematopoietic stem cell transplantation in SARSCoV2 positive recipient, risk-benefit balance between infection and leukemia 163
A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients 162
48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study 161
Candidemia in COVID-19 patients: incidence and characteristics in a prospective cohort compared to historical non-COVID-19 controls 161
Levofloxacin prophylaxis vs no prophylaxis in neutropenic patients within an endemic country for carbapenem-resistant GNB 158
Biobanking for COVID-19 research 157
A follow-up study in asymptomatic HIV patients 153
Outcome of Darunavir–Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological Failure 152
Impact of Levofloxacin for Prophylaxis of Pre-engraftment Bloodstream Infections after Allogeneic HSCT: A single-center Matched Analysis in an Endemic Country for Carbapenem-resistant Gram-negative Bacteria 150
Continuous positive airway pressure and pronation outside the Intensive Care Unit in COVID-19 acute respiratory distress syndrome 149
Trends of Antimicrobial Susceptibility of Neisseria gonorrhoeae Isolates between 2012 and 2023: Results from an Open Italian Cohort 148
Mpox Outbreak 2022: A Comparative Analysis of the Characteristics of Individuals Receiving MVA-BN Vaccination and People Diagnosed with Mpox Infection in Milan, Italy 146
Characteristics of HIV pre-exposure prophylaxis users at first PrEP counselling visit: the CSL-PrEP cohort 146
Human Monkeypox Experience in a Tertiary Level Hospital in Milan, Italy, between May and October 2022: Epidemiological Features and Clinical Characteristics 142
High-Risk Neutropenic Fever and Invasive Fungal Diseases in Patients with Hematological Malignancies 141
A case of breakthrough mpox infection in an individual non-responder to MVA-BN vaccination 141
Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial 139
Publisher Correction: Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19 (Scientific Reports, (2020), 10, 1, (21291), 10.1038/s41598-020-78039-1) 137
Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study 136
A whole-genome association study of major determinants for host control of HIV-1 134
Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV 133
HIV viral load monitoring during monkeypox virus infection among people with HIV 132
Analytical treatment interruption in chronic HIV-1 infection: Time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study) 132
Factors Associated with Low-Level Viremia in People Living with HIV in the Italian Antiviral Response Cohort Analysis Cohort: A Case-Control Study 131
Coadministration of isavuconazole and sirolimus in allogeneic hematopoietic stem cell transplant recipients 130
Antibiotic appropriateness for Gram-negative bloodstream infections: impact of infectious disease consultation 129
Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Post-transplant cyclophosphamide to overcome the HLA-matching barrier 129
Testosterone in males with COVID-19: A twelve-month cohort study 128
Cardiac implantable electronic device infections: impact of initiation of antimicrobial treatment before or after device removal on microbiological yield 128
Subclinical myocardial dysfunction in patients recovered from COVID-19 128
Profiling Covid-19 patients with respect to level of severity: an integrated statistical approach 127
Non-O1 and non-O139 Vibrio cholerae Septicemia and Cellulitis: a Case Report 127
Risk of mortality in people with chronic liver diseases hospitalized for Coronavirus disease of 2019 (COVID-19) in a tertiary hospital in Lombardy, Italy 127
Dynamics of HIV-1 POL antibodies after ART in chronic HIV-1 infection 127
Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study 127
Implementation of recombinant anti-herpes zoster vaccination in people living with HIV: a single-center experience 126
Viral Hepatitis and Human Papillomavirus Vaccination during HIV Pre-Exposure Prophylaxis: Factors Associated with Missed Vaccination 125
Mpox in people with past infection or a complete vaccination course: a global case series 125
COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike Receptor Binding Domain 125
Post-neurosurgical Nocardia meningoventriculitis: a case report and review of the literature 124
Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy 124
Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study) 124
Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy) 123
Is SARS-CoV-2-induced disease a decisive factor influencing testosterone in males? Findings from a case-control ex post facto study 123
SARS-CoV-2 IgG/IgM Rapid Test as a Diagnostic Tool in Hospitalized Patients and Healthcare Workers, at a large Teaching Hospital in northern Italy, during the 2020 COVID-19 Pandemic 123
Achieving virological control in pan-resistant HIV-1 infection: A case series 122
Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients 121
Treatment success of rescue regimens after dual therapy failure in people living with HIV in a real-life setting 121
Sexually transmitted infections in men who have sex with men with tenofovir/emtricitabine- or cabotegravir-resistant HIV 121
Exploring the Association between Delirium and Malnutrition in COVID-19 Survivors: A Geriatric Perspective 120
Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial 120
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort 119
Alterations in glutamate, arginine, and energy metabolism characterize cerebrospinal fluid and plasma metabolome of persons with HIV-associated dementia 119
Breakthrough monkeypox infection among individuals previously immunized with smallpox or monkeypox vaccination 118
Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort 118
Circulating cathodic antigen (CCA) urine rapid test for diagnosis of Schistosoma mansoni infestation: preliminary data of a cohort study of Egyptian patients coming from an endemic area 118
Evaluation of analytical performance of the STANDARDTM M10 MPX/OPX assay for the simultaneous DNA detection and clade attribution of Monkeypox virus 117
Coronavirus Disease 2019 in Recipient of Allogeneic Hematopoietic Stem Cell Transplantation: Life-threating Features Within the Early Post-engraftment Phase 117
Probable West Nile Virus hepatitis: Case report 116
High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy 116
High-dose anakinra in addition to standard of care including corticosteroids in patients with severe COVID-19 treated with non-invasive ventilation 116
Severely low testosterone in males with COVID-19: a case-control study 116
Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV 116
Monkeypox infection among men who have sex with men: PCR testing on seminal fluids 115
Risk of Cardiovascular Diseases or Mortality in People with Higher Values of HIV-1 DNA 115
Changes in homeostatic model assessment for insulin resistance (HOMA-IR) index in treated HIV-1 infected people on virological suppression who switched to a different antiretroviral regimen 115
Serum IgG1 and IgG4 could contribute to partial control of viral rebound in chronically HIV-1-infected patients 115
Clinico-Virological Outcomes and Mutational Profile of SARS-CoV-2 in Adults Treated with Ribavirin Aerosol for COVID-19 Pneumonia 114
Rectal Lymphogranuloma venereum among Men who Have Sex with Men: 7 versus 21 Days Doxycycline Effectiveness 114
One Year of Long-Acting Cabotegravir and Rilpivirine in People With Human Immunodeficiency Virus and Long Exposure to Antiretroviral Therapy: Data From the SCohoLART Study 114
Combination of High-Dose Daptomycin and Ceftriaxone for Cardiac Implantable Electronic Device Infections: A 10-Year Experience 114
Beyond stigma: Monkeypox infection in a 27-year-old woman 113
Factors Associated with Health Care Providers' Preference for Forgoing an Oral Lead-In Phase When Initiating Long-Acting Injectable Cabotegravir and Rilpivirine in the SOLAR Clinical Trial 113
Effectiveness and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide therapy in an observational Italian cohort: The DIAMANTE study 113
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors 113
Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals 113
T and B cell responses to cytomegalovirus antigens in healthy blood donors and bone marrow transplant recipients 113
Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor-Based Combination Antiretroviral Therapy: The D:A:D Study 112
Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation 112
Long-term outcome in a person with pandrug-resistant HIV: the added value of a multidisciplinary approach 111
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry 111
Combined plasma levels of IL-10 and testosterone, but not soluble HLA-G5, predict the risk of death in COVID-19 patients 111
Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study 111
A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial 111
Antiretroviral therapy in geriatric HIV patients: The GEPPO cohort study 111
Totale 15.336
Categoria #
all - tutte 319.131
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 319.131


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022416 0 0 0 137 26 29 36 64 36 29 16 43
2022/20232.835 1.206 552 220 27 36 257 175 185 99 19 35 24
2023/20242.162 45 66 641 171 178 410 59 180 8 45 113 246
2024/20259.554 1.078 150 178 281 363 852 2.013 777 1.368 1.050 587 857
2025/202630.943 2.115 2.342 2.648 4.230 2.273 989 2.700 2.187 7.675 1.818 1.094 872
2026/20277.838 936 1.854 1.735 3.313 0 0 0 0 0 0 0 0
Totale 54.414